Drug intelligence / Profile preview

PB-01

Development stage
Unknown
Lead developer
ABX
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

PB-01 is a gallium-68 (^68Ga) labeled radiopharmaceutical developed by Primo Biotechnology for the diagnostic imaging of metastatic prostate cancer. As a radiotracer designed for use with PET/CT imaging technology, PB-01 specifically targets the Prostate Specific Membrane Antigen (PSMA), a cell-surface glycoprotein that is significantly overexpressed in prostate cancer cells. By binding to PSMA, the drug allows for the precise detection and monitoring of primary and metastatic lesions. PB-01 is the Taiwanese market equivalent of Radelumin, a diagnostic agent approved in Europe, and is being developed in collaboration with the German company ABX advanced biochemical compounds GmbH to improve precision oncology and patient staging in Taiwan.

Brand names
IlluccixLocametz
Other names
68Ga-labeled PSMA-targeting radiopharmaceutical68Ga-PSMA-11gallium Ga 68 gozetotide
02

Targets

PSMA (Prostate-specific membrane antigen)

Beyond the preview

Go deeper on PB-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PB-01.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call